Dusquetide

Soligenix, Inc. initiates patient enrollment for FLASH2, a Phase 3 study on HyBryteTM for treating cutaneous T-cell lymphoma (CTCL). Building on previous successful trials, FLASH2 aims to confirm HyBryte's efficacy and safety over 18 weeks of continuous treatment, offering a promising alternative for early-stage CTCL patients.

Soligenix announces continued improvement in HyBryte™-treated patients and lesions post-treatment, with statistically significant efficacy against plaque lesions compared to Valchlor®, and no safety concerns raised.

Soligenix forms European Medical Advisory Board to guide Phase 3 study of HyBryte™ in CTCL, targeting enrollment of 80 patients in U.S. and Europe by end of 2024, with results expected in 2026.

Soligenix opens patient enrollment for Phase 2 study DUS-AUBD-01 evaluating SGX945 (dusquetide) for Behçet's Disease, aiming to address significant unmet medical needs.

Soligenix opens patient enrollment for Phase 2 study DUS-AUBD-01, evaluating SGX945 (dusquetide) for Behçet's Disease treatment.

Soligenix initiates Phase 2 trial of SGX945 (dusquetide) for Behçet's Disease treatment, aiming to address unmet medical needs with a focus on severe ulcers. The open-label study will enroll 25 patients with mild to moderate Behçet's Disease, evaluating SGX945's efficacy in lesion clearance and quality of life. Dusquetide, an innate defense regulator, has shown promise in previous studies for oral mucositis and may offer significant relief for Behçet's Disease patients.